Category: Science & Policy

  • Seeing “Being Sick” Through Three Lenses: Disease, Illness, and Sickness

    When we feel unwell, we reach for our phones and type the same familiar words: “I’m sick.”

    In Japanese, byōki (病気) is a generous container. It can hold a mild cold, a chronic condition, a diagnosable pathology, or simply the vague heaviness of a day when the world feels too bright.

    But in medical anthropology, sociology, and philosophy, “being sick” is not a single state.

    It is a three‑layered phenomenon, each layer revealing a different truth about the human condition: Disease, Illness, and Sickness.

    In an age when AI can analyze data in seconds and propose optimal treatment plans, this triad reminds us of something essential: health is never just biological. It is lived, narrated, negotiated. It is where the algorithm ends and the person begins.

    1. Etymology: The Historical Origins of the Three Words

    Before they became academic terms, these words belonged to the everyday lives of medieval Europeans. They carried the weight of discomfort, misfortune, and human fragility. Their evolution reflects the gradual separation of body, self, and society in Western thought. 

    Disease: Away from Ease

    Origin: Old French desaise (also attested as desease) — des- “away from” + aise “comfort/ease”. 

    Literal Meaning: “Lack of comfort” or “physical inconvenience.”

    Evolution: Until the late Middle Ages, disease referred broadly to discomfort, inconvenience, or misfortune. Only with the rise of anatomical science and pathological thinking did it narrow into its modern biomedical meaning.

    Illness: The Texture of Feeling Ill 

    Origin: Formed within English from ill (Old Norse illr, “bad/difficult”) + ‑ness.

    Literal Meaning: “The state of being in bad shape.”

    Evolution: In early modern English, illness could refer to moral badness or wickedness. By the late 17th century, it shifted almost entirely to bodily or mental unwellness.

    Sickness: The Social Status of the Sick

    Origin: Old English seocnes (seoc, “ill, feeble, grieving”).

    Literal Meaning: “A weakened or unwell condition,” often blending physical frailty with emotional or spiritual distress.

    Evolution: Long used interchangeably with illness, but 20th‑century sociology refined it to mean the socially recognized status of being unwell.

    2. The Triad Model: Three Ways of Seeing a Malady 

    In the late 20th century, scholars like Andrew Twaddle, Leon Eisenberg, Arthur Kleinman, Horacio Fabrega, and Byron Good reframed these words as three analytic perspectives.

    “Patients suffer illnesses; physicians diagnose and treat diseases.”

    — Leon Eisenberg (1977)

    This distinction became foundational in medical anthropology and patient‑centered care.

    Disease (The Medical Lens)

    Focus: Biological, pathological, biochemical abnormalities

    Characteristics: Objective, measurable, standardized

    Goal: Cure — restoring physiological function or correcting the underlying abnormality

    Illness (The Personal Lens)

    Focus: The subjective, first‑person experience of being unwell

    Characteristics: Phenomenological, narrative, deeply personal

    Goal: Care — alleviating suffering and helping the person make sense of their experience

    Sickness (The Social Lens)

    Focus: Social identity, institutional labels, cultural expectations

    Characteristics: Inter‑subjective, political, regulatory

    Goal: Social management — allocating resources, defining rights, maintaining social order

    3. When the Three Lenses Align—and When They Don’t 

    Philosopher Bjørn Hofmann visualized these concepts as a Venn diagram. 

    When all three overlap, the world feels coherent:

    you feel unwell (Illness), the doctor finds a cause (Disease), and society acknowledges your condition (Sickness).

    But often, the circles drift apart, creating ethical, clinical, and social dilemmas.

    Pattern A — Disease (+), Illness (–), Sickness (–)

    A biological abnormality exists, but the person feels fine and society does not treat them as a patient.

    Examples: Asymptomatic hypertension, early‑stage carcinoma, viral incubation

    Dilemma: Overdiagnosis and anxiety in otherwise healthy individuals

    Pattern B — Disease (–), Illness (+), Sickness (–)

    The person suffers, but tests show nothing abnormal.

    Examples: Fibromyalgia, ME/CFS, Long COVID, early psychosomatic disorders

    Dilemma: Patients are dismissed as “lazy” or “imagining it,” losing both medical validation and social support

    Pattern C — Disease (–), Illness (–), Sickness (+)

    No biological defect or subjective suffering, yet society labels the state as a medical condition.

    Examples: Historical pathologization of homosexuality

    Dilemma: Medicalization of social or moral categories

    4. The Social Architecture of Being Sick 

    The “Sick Role” (Talcott Parsons, 1951)

    Parsons argued that sickness is a regulated social role with: 

    Privileges:

    • Exemption from normal responsibilities
    • Exemption from blame

    Obligations:

    • Wanting to recover
    • Seeking competent medical help and cooperating with it

    Failure to meet these obligations risks losing legitimacy and being labeled as malingering. 

    A Parallel with WHO’s Classic Framework

    The triad mirrors the WHO’s 1980 model (later the ICF):

    • Impairment (body level): Disease
    • Disability (activity level): Illness
    • Handicap (participation level): Sickness

    This alignment underscores that health is simultaneously biological, experiential, and social. 

    5. Japan: A Culture Where “Byōki” Holds Everything 

    To apply this triad to Japan, we must first acknowledge a linguistic truth: Japanese does not naturally separate these three layers. 

    The Elasticity of Byōki 

    In Japanese, byōki can refer to: 

    • a cold
    • a diagnosable pathology
    • chronic conditions
    • or simply “not feeling well today”

    Unlike English, Japanese rarely distinguishes between:

    • biological abnormality (disease)
    • subjective suffering (illness)
    • social recognition and institutional status (sickness)

    This linguistic compression shapes social expectations. Without distinct terms for disease, illness, and sickness, the boundaries blur. 

    The Struggle for Sickness Recognition

    In many workplaces, saying “I don’t feel well” (illness) is insufficient.

    A doctor’s note—proof of disease—is required to unlock social protections (sickness), such as:

    • paid sick leave
    • workplace accommodations
    • Shōbyō‑teatekin (傷病手当金)

    In Japan, sickness is tightly regulated by certification, often more so than in Western contexts.

    The Stigma of Sickness in the COVID Era 

    During the pandemic, infection became more than a biological event.

    It became a social identity, sometimes a dangerous one.

    People were judged not for how they felt, but for what they represented:

    • risk
    • irresponsibility
    • contamination
    • moral failure

    This is sickness in its purest form:

    the social meaning of being unwell, detached from biology or experience.

    Conclusion: Balancing the Ecosystem of Health

    None of these three lenses is superior. They are mutually dependent pieces of a larger ecosystem.

    To heal the body, we must address disease.

    To ease suffering, we must understand illness.

    To protect the vulnerable, we must recognize sickness.

    When we look at medicine through this balanced, flat perspective, we stop blaming doctors for being overly analytical, and we stop blaming patients for having subjective pain that science cannot yet map. By understanding where the boundaries of Disease, Illness, and Sickness lie, we can build a more empathetic, integrated approach to human suffering.

  • Japan’s HTA System and the 2026 Reform: A Comprehensive Guide

    With the 2026 revisions shaping the landscape of healthcare policy, I felt the need to map out the current state of Japan’s HTA system. As someone working at the intersection of data and policy, this guide is my attempt to clarify how we measure “value” in modern medicine.

    Introduction: The Concept of “Value for Money” in Medicine

    Japan has a universal healthcare system that provides high-quality medical care to everyone. However, many ultra-high-cost drugs—like new cancer therapies and gene treatments—are appearing now. This makes it difficult to keep the national health insurance budget sustainable.

    Therefore, Japan started the Health Technology Assessment (HTA) system in April 2019. The goal is to check “Value for Money.” The system ensures that the price of a drug matches the clinical benefit it gives to patients and the healthcare system.

    Chapter 1. Japan’s Unique “Post-Reimbursement” Model

    The Japanese HTA system is structurally different from many other countries.

    1. Price Adjustment Instead of a Gatekeeper

    In some countries like the UK, if a drug gets a negative HTA result, the insurance will not cover it. Japan is different. Japan puts patient access first. Therefore, almost all approved drugs get insurance coverage first. The government uses HTA as a “complementary tool” to adjust the drug’s price (up or down) after it is already on the market.

    2. The Core Metrics: QALY and ICER

    To measure “value” scientifically, Japan uses two main international metrics:

    • QALY (Quality-Adjusted Life Year): This measures both the length of life (survival) and the quality of life (QOL). One QALY means one year of life in perfect health.
    • ICER (Incremental Cost-Effectiveness Ratio): This formula calculates the extra cost needed to get one extra QALY compared to existing standard treatments (i.e., standard of care, or the chosen comparator).
      ICER = \frac{\text{Cost (New Drug)} – \text{Cost (Existing Treatment)}}{\text{Effect (New Drug)} – \text{Effect (Existing Treatment)}}

    3. Thresholds for Value

    In Japan, if the ICER is below 5 million yen per QALY, the drug is “cost-effective.” The government keeps its price. For cancer or rare diseases, the threshold increases to 7.5 million yen per QALY because these patients have high unmet needs.

    Chapter 2. The 2026 (Reiwa 8) Reform: A New Era for HTA

    The April 2026 reform updates how Japan evaluates drug costs. The evaluations are becoming more strict and dynamic.

    1. The New Price Adjustment Formula

    If a new drug does not show an additional benefit compared to existing treatments, the government uses a new formula. This formula matches the new drug’s price closer to the existing treatment’s price (the comparator price).

    • New Formula:
      \text{Adjusted Price} = \text{Pre-adjusted Price} \times \frac{\text{Comparator Daily Drug Price}}{\text{Target Daily Drug Price}}
    • 15% Reduction Cap: A very big price drop can make drug supply unstable. Therefore, the maximum price cut from this HTA formula is limited to 15% (the price will not go below 85% of the original price).

    2. Dynamic Re-Evaluation (H3 Category)

    HTA is not a one-time check at the start. Under the 2026 rules, the government can evaluate a drug again (under category H3) even after the first review is finished. This happens if there is important new clinical data or new global HTA results.

    3. Terminology and Caregiving Costs

    The government changed the term “Additional Benefit” to “Improvement in health outcome indicators relative to the comparator.” This avoids confusion with other drug pricing rules. Also, the 2026 rules give clearer instructions on how to include caregiving costs. This recognizes that good drugs can reduce the burden on family members.

    4. Implementation Schedule

    For drugs that report HTA results after April 2026, the price adjustments will wait until September 2026. This gives the government time to check the technical effects of the new reform before changing prices.

    Chapter 3. Selection Criteria: The “H-Category” Framework

    Not all medicines go through HTA. The government selects drugs based on their impact on the national health budget using five categories.

    CategoryTimingMain Criteria
    H1At ListingHigh-budget drugs (predicted peak sales >50 billion yen).
    H2At ListingPredicted peak sales >10 billion yen and high innovation premiums.
    H3Post-ListingExpanding products with sales over 5 billion yen, or re-designated items.
    H4LegacyLarge-market drugs listed before the 2019 policy started.
    H5SimilarityFollow-on drugs adjusted based on the result of a similar representative drug.

    Exemptions: Drugs for ultra-rare diseases (designated intractable diseases) or pediatric conditions usually do not go through HTA. This ensures patients can get essential treatments quickly.

    Chapter 4. Technical Guidelines for Analysis

    The C2H (Center for Outcomes Research and Economic Evaluation for Health) checks the technical quality of the data.

    • EQ-5D-5L Standard: Japan prefers to measure quality of life (QOL) using the EQ-5D-5L tool. Companies can convert other scales (“mapping”), but review committees check this very strictly because it introduces uncertainty.
    • Perspective: The analysis must use the “Public Payer Perspective.” This includes public insurance costs and patient co-payments.
    • Discounting: Future costs and health effects decrease by 2.0% per year to calculate their value today.

    Chapter 5. International Comparison: 2026 Global Trends

    Japan is changing its pricing formulas, but other major HTA bodies are also changing their policies in 2026.

    Country2026 Policy OutlookHTA Role
    Japan15% cap on HTA price cuts; dynamic re-evaluation.Adjusts prices after the drug is listed.
    UK (NICE)Increased the threshold from £20k-£30k to £25k-£35k per QALY in April 2026.Decides if the insurance covers the drug (Gatekeeper).
    GermanyFocuses on “added therapeutic benefit” for price talks.Price negotiation based on evidence.

    The UK’s NICE increased its threshold for the first time in over 20 years to support industry growth and patient access. This is different from Japan, which focuses on controlling costs with mathematical formulas.

    Chapter 6. Real-World Evidence and Success Stories

    Japan is using more Real-World Data (RWD), such as health insurance claims (receipt data), to confirm a drug’s value in real clinical practice.

    • Success Case (Dapagliflozin): The government evaluated this SGLT2 inhibitor for Chronic Kidney Disease (CKD). The analysis combined clinical trial data with Japanese RWD. It proved that the drug significantly reduces long-term dialysis costs. The ICER was about 1.28 million yen per QALY. This is well below the 5 million yen threshold, proving the drug is highly cost-effective.

    Conclusion

    In 2026, Japan enters the “Second Stage” of its HTA system. Evaluating a drug’s value is now a dynamic process that lasts throughout its time on the market. The 15% reduction cap and the new re-evaluation rules mean that economic evidence must be strong not just at launch, but always. For everyone in the healthcare industry, showing long-term economic value with Japanese data is now the most important key to success.

    For me, the true “art of learning” in this field is not just tracking the changing formulas, but understanding how these policies ultimately affect real-world well-being. Keeping a steady eye on this balance is a core part of my ongoing inquiry.


    Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or position of any affiliated organizations.